Radiopharmaceuticals in Neurological and Psychiatric Disorders
Autor: | Valotassiou, Varvara, Wozniak, Greta, Sifakis, N., Demakopoulos, Nikolaos, Georgoulias, Panagiotis |
---|---|
Přispěvatelé: | Wozniak, Greta [0000-0002-8939-0927], Georgoulias, Panagiotis [0000-0002-6493-705X] |
Rok vydání: | 2008 |
Předmět: |
Neurologic disease
Dopaminergic system Fluorodeoxyglucose f 18 Review Mental disorders Serotonin 1a receptor Single-photon emission computed tomography Treatment response Neurofibrillary tangle 6 fluorodopa f 18 Levodopa Epilepsy Pramipexole Brain perfusion Hexamethylpropylene amine oxime technetium tc 99m Pharmacology (medical) Opiate receptor General Pharmacology Toxicology and Pharmaceutics Cerebrovascular disease Tomography Stroke Priority journal Blood-brain barrier Neuroleptic agent Disorders medicine.diagnostic_test Depression Spect Serotoninergic system Mental Disorders Brain General Medicine Early diagnosis Parkinson disease Cerebral blood flow Blood brain barrier Blood-Brain Barrier Positron emission tomography Dopamine transporter Neurological Differential diagnosis Alzheimer disease Human Single photon emission computer tomography medicine.medical_specialty Brain blood flow Molecular imaging Neuroimaging Flumazenil c 11 Citalopram Cysteine ethyl ester tc 99m Brain metabolism Selegiline medicine Animals Humans Dementia Dopamine 2 receptor Radiopharmaceutical agent Scintiscanning Psychiatry Tomography Emission-Computed Single-Photon Senile plaque Animal business.industry Cholinergic system Mental disease Benzodiazepine receptor Nervous system diseases medicine.disease Diagnostic agent Pet Raclopride c 11 Positron-Emission Tomography Schizophrenia Psychiatric Receptor binding Single-photon Positron-emission tomography Nervous System Diseases Radiopharmaceuticals business Emission-computed |
Zdroj: | Current Clinical Pharmacology |
ISSN: | 1574-8847 |
Popis: | The development of functional brain nuclear medicine techniques and their application in the investigation of neuropsychiatric disorders, have contributed significantly in the illumination of the underlying pathophysiological processes of these disorders. Furthermore, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) brain studies provide information in early diagnosis, differential diagnosis, development of new drugs, and monitoring the response to therapeutic management. SPECT and PET brain imaging require the use of radiopharmaceuticals that cross the intact Blood Brain Barrier (BBB). Such radiotracers have been used in regional Cerebral Blood Flow (rCBF) SPECT and PET imaging and brain metabolism imaging with PET; these are well established methods in the diagnosis and management of various cerebral vascular diseases (e.g. stroke, dementia, epilepsy). Advances in radiotracer chemistry have resulted in the development of molecular imaging which represents the molecular and cellular processes of neurochychiatric diseases. SPECT and PET molecular imaging has become available for the study of acetylcholinergic, dopaminergic and serotonergic systems, as well as for benzodiazepine and opioid receptors, with promising results. More studies are needed to validate the role of molecular imaging in the clinical practice of neuropsychiatric disorders. © 2008 Bentham Science Publishers Ltd. 3 2 99 107 |
Databáze: | OpenAIRE |
Externí odkaz: |